|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gennigens C, De Cuypere M, Hermesse J,
Kridelka F and Jerusalem G: Optimal treatment in locally advanced
cervical cancer. Expert Rev Anticancer Ther. 21:657–671.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy, and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.PubMed/NCBI
|
|
5
|
Nguyen VT, Winterman S, Playe M, Benbara
A, Zelek L, Pamoukdjian F and Bousquet G: Dose-intense
cisplatin-based neoadjuvant chemotherapy increases survival in
advanced cervical cancer: An up-to-date meta-analysis. Cancers
(Basel). 14(842)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sala P, Bogliolo S, Barra F, Fazio A,
Maramai M, Cassani C, Gardella B, Babilonti L, Giannelli F,
Mammoliti S, et al: Neoadjuvant chemotherapy followed by radical
surgery versus concurrent chemo-radiotherapy in the treatment of
locally advanced cervical cancer: A multicenter retrospective
analysis. J Invest Surg. 35:308–314. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yeatman TJ: A renaissance for SRC. Nat Rev
Cancer. 4:470–480. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Elias D and Ditzel HJ: Fyn is an important
molecule in cancer pathogenesis and drug resistance. Pharmacol Res.
100:250–254. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Noronha G, Barrett K, Boccia A, Brodhag T,
Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, et al:
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo
[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine-a
potent, orally active Src kinase inhibitor with anti-tumor activity
in preclinical assays. Bioorg Med Chem Lett. 17:602–608.
2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fresno Vara JA, Cáceres MA, Silva A and
Martín-Pérez J: Src family kinases are required for prolactin
induction of cell proliferation. Mol Biol Cell. 12:2171–2183.
2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
12
|
Valadan R, Hedayatizadeh-Omran A,
Alhosseini-Abyazani MN, Amjadi O, Rafiei A, Tehrani M and
Alizadeh-Navaei R: Data supporting the design and evaluation of a
universal primer pair for pseudogene-free amplification of HPRT1 in
real-time PCR. Data Brief. 4:384–389. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mori T, Hosokawa K, Sawada M, Kuroboshi H,
Tatsumi H, Koshiba H, Okubo T and Kitawaki J: Neoadjuvant weekly
carboplatin and paclitaxel followed by radical hysterectomy for
locally advanced cervical cancer: Long-term results. Int J Gynecol
Cancer. 20:611–616. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shoji T, Takatori E, Furutake Y, Takada A,
Nagasawa T, Omi H, Kagabu M, Honda T, Miura F, Takeuchi S, et al:
Phase II clinical study of neoadjuvant chemotherapy with
CDDP/CPT-11 regimen in combination with radical hysterectomy for
cervical cancer with a bulky mass. Int J Clin Oncol. 21:1120–1127.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boggon TJ and Eck MJ: Structure and
regulation of Src family kinases. Oncogene. 23:7918–7927.
2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vlahovic G and Crawford J: Activation of
tyrosine kinases in cancer. Oncologist. 8:531–538. 2003.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Frame MC: Src in cancer: Deregulation and
consequences for cell behaviour. Biochim Biophys Acta.
1602:114–130. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Campbell EJ, McDuff E, Tatarov O, Tovey S,
Brunton V, Cooke TG and Edwards J: Phosphorylated c-Src in the
nucleus is associated with improved patient outcome in ER-positive
breast cancer. Br J Cancer. 99:1769–1774. 2008.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Saito YD, Jensen AR, Salgia R and Posadas
EM: Fyn: A novel molecular target in cancer. Cancer. 116:1629–1637.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang C, Zhou J, Nie Y, Guo G, Wang A and
Zhu X: A new finding in the key prognosis-related proto-oncogene
FYN in hepatocellular carcinoma based on the WGCNA hub-gene
screening trategy. BMC Cancer. 22(380)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jiang P, Li Z, Tian F, Li X and Yang J:
Fyn/heterogeneous nuclear ribonucleoprotein E1 signaling regulates
pancreatic cancer metastasis by affecting the alternative splicing
of integrin β1. Int J Oncol. 51:169–183. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lyu SC, Han DD, Li XL, Ma J, Wu Q, Dong
HM, Bai C and He Q: Fyn knockdown inhibits migration and invasion
in cholangiocarcinoma through the activated AMPK/mTOR signaling
pathway. Oncol Lett. 15:2085–2090. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang X, Huang Z, Guo Y, Xiao T, Tang L,
Zhao S, Wu L, Su J, Zeng W, Huang H, et al: The phosphorylation of
CD147 by Fyn plays a critical role for melanoma cells growth and
metastasis. Oncogene. 39:4183–4197. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yu J, Zhou Z, Wei Z, Wu J, OuYang J, Huang
W, He Y and Zhang C: FYN promotes gastric cancer metastasis by
activating STAT3-mediated epithelial-mesenchymal transition. Transl
Oncol. 13(100841)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu D, Gao M, Wu K, Zhu D, Yang Y and Zhao
S: LINC00152 facilitates tumorigenesis in esophageal squamous cell
carcinoma via miR-153-3p/FYN axis. Biomed Pharmacother.
112(108654)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Comba A, Dunn PJ, Argento AE, Kadiyala P,
Ventosa M, Patel P, Zamler DB, Núñez FJ, Zhao L, Castro MG and
Lowenstein PR: Fyn tyrosine kinase, a downstream target of receptor
tyrosine kinases, modulates antiglioma immune responses. Neuro
Oncol. 22:806–818. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mi H, Wang X, Wang F, Li L, Zhu M, Wang N,
Xiong Y and Gu Y: miR-381 induces sensitivity of breast cancer
cells to doxorubicin by inactivation of MAPK signaling via FYN. Eur
J Pharmacol. 839:66–75. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Elias D, Vever H, Lænkholm AV, Gjerstorff
MF, Yde CW, Lykkesfeldt AE and Ditzel HJ: Gene expression profiling
identifies FYN as an important molecule in tamoxifen resistance and
a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene. 34:1919–1927. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Grosso S, Puissant A, Dufies M, Colosetti
P, Jacquel A, Lebrigand K, Barbry P, Deckert M, Cassuto JP, Mari B
and Auberger P: Gene expression profiling of imatinib and
PD166326-resistant CML cell lines identifies Fyn as a gene
associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther.
8:1924–1933. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Liu G, Ji L, Ke M, Ou Z, Tang N and Li Y:
miR-125a-3p is responsible for chemosensitivity in PDAC by
inhibiting epithelial-mesenchymal transition via Fyn. Biomed
Pharmacother. 106:523–531. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bose RN: Biomolecular targets for platinum
antitumor drugs. Mini Rev Med Chem. 2:103–111. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang Q, Shi S, He W, Padilla MT, Zhang L,
Wang X, Zhang B and Lin Y: Retaining MKP1 expression and
attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance
through miR-940 inhibition. Oncotarget. 5:1304–1314.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu
X, Yang Y, Mo W, Huang W, Khoo SK, et al: Role of eIF3a in
regulating cisplatin sensitivity and in translational control of
nucleotide excision repair of nasopharyngeal carcinoma. Oncogene.
30:4814–4823. 2011.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Surowiak P, Materna V, Kaplenko I,
Spaczyński M, Dietel M, Lage H and Zabel M: Augmented expression of
metallothionein and glutathione S-transferase pi as unfavourable
prognostic factors in cisplatin-treated ovarian cancer patients.
Virchows Arch. 447:626–633. 2005.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Morimoto A, Serada S, Enomoto T, Kim A,
Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M,
et al: Annexin A4 induces platinum resistance in a chloride-and
calcium-dependent manner. Oncotarget. 5:7776–7787. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liu RY, Dong Z, Liu J, Zhou L, Huang W,
Khoo SK, Zhang Z, Petillo D, The BT, Qian CN and Zhang JT:
Overexpression of asparagine synthetase and matrix
metalloproteinase 19 confers cisplatin sensitivity in
nasopharyngeal carcinoma cells. Mol Cancer Ther. 12:2157–2166.
2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Imai K, Fukuda T, Wada T, Kawanishi M,
Tasaka R, Yasui T and Sumi T: UCP2 expression may represent a
predictive marker of neoadjuvant chemotherapy effectiveness for
locally advanced uterine cervical cancer. Oncol Lett. 14:951–957.
2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Shimomura M, Fukuda T, Awazu Y, Nanno S,
Inoue Y, Matsubara H, Yamauchi M, Yasui T and Sumi T: PRMT1
expression predicts response to neoadjuvant chemotherapy for
locally advanced uterine cervical cancer. Oncol Lett.
21(150)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Inoue Y, Fukuda T, Nanno S, Awazu Y,
Shimomura M, Matsubara H, Yamauchi M, Yasui T and Sumi T: T-box 2
expression is a useful indicator of the response to neoadjuvant
chemotherapy for patients with locally advanced uterine cervical
squamous cell carcinoma. Oncol Lett. 22(755)2021.PubMed/NCBI View Article : Google Scholar
|
